This handbook, now in its eighth year, seeks to analyze the trends in financial reporting across the pharmaceuticals industry and provide insights from KPMG partners and managers around the world.
We have analyzed 2009 financial reporting data for the largest global pharmaceutical companies. Our analysis shows an increase in reporting risks related to strategic alliances and drug development spending, alongside limited R&D investment as the industry shifts towards a more challenging cost-oriented environment, and the demand for more innovative medicines continues.
KPMG’s Pharmaceuticals Disclosures Handbook is designed to serve as a reference document for the stakeholders of financial reporting in the pharmaceuticals sector.